Global Short-acting EPO Drugs Market Insights, Forecast to 2029

TABLE OF CONTENTS

1 Study Coverage

• 1.1 Short-acting EPO Drugs Product Introduction
• 1.2 Market by Type
  • 1.2.1 Global Short-acting EPO Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
  • 1.2.2 Epoetin-alfa
  • 1.2.3 Epoetin-beta
  • 1.2.4 Darbepoetin-alfa
  • 1.2.5 Others
• 1.3 Market by Application
  • 1.3.1 Global Short-acting EPO Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
  • 1.3.2 Anemia
  • 1.3.3 Kidney Disorders
  • 1.3.4 Others
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Executive Summary

• 2.1 Global Short-acting EPO Drugs Sales Estimates and Forecasts 2018-2029
• 2.2 Global Short-acting EPO Drugs Revenue by Region
  • 2.2.1 Global Short-acting EPO Drugs Revenue by Region: 2018 VS 2022 VS 2029
  • 2.2.2 Global Short-acting EPO Drugs Revenue by Region (2018-2023)
  • 2.2.3 Global Short-acting EPO Drugs Revenue by Region (2024-2029)
  • 2.2.4 Global Short-acting EPO Drugs Revenue Market Share by Region (2018-2029)
• 2.3 Global Short-acting EPO Drugs Sales Estimates and Forecasts 2018-2029
• 2.4 Global Short-acting EPO Drugs Sales by Region
  • 2.4.1 Global Short-acting EPO Drugs Sales by Region: 2018 VS 2022 VS 2029
  • 2.4.2 Global Short-acting EPO Drugs Sales by Region (2018-2023)
  • 2.4.3 Global Short-acting EPO Drugs Sales by Region (2024-2029)
  • 2.4.4 Global Short-acting EPO Drugs Sales Market Share by Region (2018-2029)
• 2.5 US & Canada
• 2.6 Europe
• 2.7 China
• 2.8 Asia (excluding China)
• 2.9 Middle East, Africa and Latin America

3 Competition by Manufactures

• 3.1 Global Short-acting EPO Drugs Sales by Manufacturers
  • 3.1.1 Global Short-acting EPO Drugs Sales by Manufacturers (2018-2023)
  • 3.1.2 Global Short-acting EPO Drugs Sales Market Share by Manufacturers (2018-2023)
  • 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Short-acting EPO Drugs in 2022
• 3.2 Global Short-acting EPO Drugs Revenue by Manufacturers
  • 3.2.1 Global Short-acting EPO Drugs Revenue by Manufacturers (2018-2023)
  • 3.2.2 Global Short-acting EPO Drugs Revenue Market Share by Manufacturers (2018-2023)
  • 3.2.3 Global Top 10 and Top 5 Companies by Short-acting EPO Drugs Revenue in 2022
• 3.3 Global Key Players of Short-acting EPO Drugs, Industry Ranking, 2021 VS 2022 VS 2023
• 3.4 Global Short-acting EPO Drugs Sales Price by Manufacturers
• 3.5 Analysis of Competitive Landscape
  • 3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
  • 3.5.2 Global Short-acting EPO Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
• 3.6 Global Key Manufacturers of Short-acting EPO Drugs, Manufacturing Base Distribution and Headquarters
• 3.7 Global Key Manufacturers of Short-acting EPO Drugs, Product Offered and Application
• 3.8 Global Key Manufacturers of Short-acting EPO Drugs, Date of Enter into This Industry
• 3.9 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Global Short-acting EPO Drugs Sales by Type
  • 4.1.1 Global Short-acting EPO Drugs Historical Sales by Type (2018-2023)
  • 4.1.2 Global Short-acting EPO Drugs Forecasted Sales by Type (2024-2029)
  • 4.1.3 Global Short-acting EPO Drugs Sales Market Share by Type (2018-2029)
• 4.2 Global Short-acting EPO Drugs Revenue by Type
  • 4.2.1 Global Short-acting EPO Drugs Historical Revenue by Type (2018-2023)
  • 4.2.2 Global Short-acting EPO Drugs Forecasted Revenue by Type (2024-2029)
  • 4.2.3 Global Short-acting EPO Drugs Revenue Market Share by Type (2018-2029)
• 4.3 Global Short-acting EPO Drugs Price by Type
  • 4.3.1 Global Short-acting EPO Drugs Price by Type (2018-2023)
  • 4.3.2 Global Short-acting EPO Drugs Price Forecast by Type (2024-2029)

5 Market Size by Application

• 5.1 Global Short-acting EPO Drugs Sales by Application
  • 5.1.1 Global Short-acting EPO Drugs Historical Sales by Application (2018-2023)
  • 5.1.2 Global Short-acting EPO Drugs Forecasted Sales by Application (2024-2029)
  • 5.1.3 Global Short-acting EPO Drugs Sales Market Share by Application (2018-2029)
• 5.2 Global Short-acting EPO Drugs Revenue by Application
  • 5.2.1 Global Short-acting EPO Drugs Historical Revenue by Application (2018-2023)
  • 5.2.2 Global Short-acting EPO Drugs Forecasted Revenue by Application (2024-2029)
  • 5.2.3 Global Short-acting EPO Drugs Revenue Market Share by Application (2018-2029)
• 5.3 Global Short-acting EPO Drugs Price by Application
  • 5.3.1 Global Short-acting EPO Drugs Price by Application (2018-2023)
  • 5.3.2 Global Short-acting EPO Drugs Price Forecast by Application (2024-2029)

6 US & Canada

• 6.1 US & Canada Short-acting EPO Drugs Market Size by Type
  • 6.1.1 US & Canada Short-acting EPO Drugs Sales by Type (2018-2029)
  • 6.1.2 US & Canada Short-acting EPO Drugs Revenue by Type (2018-2029)
• 6.2 US & Canada Short-acting EPO Drugs Market Size by Application
  • 6.2.1 US & Canada Short-acting EPO Drugs Sales by Application (2018-2029)
  • 6.2.2 US & Canada Short-acting EPO Drugs Revenue by Application (2018-2029)
• 6.3 US & Canada Short-acting EPO Drugs Market Size by Country
  • 6.3.1 US & Canada Short-acting EPO Drugs Revenue by Country: 2018 VS 2022 VS 2029
  • 6.3.2 US & Canada Short-acting EPO Drugs Sales by Country (2018-2029)
  • 6.3.3 US & Canada Short-acting EPO Drugs Revenue by Country (2018-2029)
  • 6.3.4 US
  • 6.3.5 Canada

7 Europe

• 7.1 Europe Short-acting EPO Drugs Market Size by Type
  • 7.1.1 Europe Short-acting EPO Drugs Sales by Type (2018-2029)
  • 7.1.2 Europe Short-acting EPO Drugs Revenue by Type (2018-2029)
• 7.2 Europe Short-acting EPO Drugs Market Size by Application
  • 7.2.1 Europe Short-acting EPO Drugs Sales by Application (2018-2029)
  • 7.2.2 Europe Short-acting EPO Drugs Revenue by Application (2018-2029)
• 7.3 Europe Short-acting EPO Drugs Market Size by Country
  • 7.3.1 Europe Short-acting EPO Drugs Revenue by Country: 2018 VS 2022 VS 2029
  • 7.3.2 Europe Short-acting EPO Drugs Sales by Country (2018-2029)
  • 7.3.3 Europe Short-acting EPO Drugs Revenue by Country (2018-2029)
  • 7.3.4 Germany
  • 7.3.5 France
  • 7.3.6 U.K.
  • 7.3.7 Italy
  • 7.3.8 Russia

8 China

• 8.1 China Short-acting EPO Drugs Market Size
  • 8.1.1 China Short-acting EPO Drugs Sales (2018-2029)
  • 8.1.2 China Short-acting EPO Drugs Revenue (2018-2029)
• 8.2 China Short-acting EPO Drugs Market Size by Application
  • 8.2.1 China Short-acting EPO Drugs Sales by Application (2018-2029)
  • 8.2.2 China Short-acting EPO Drugs Revenue by Application (2018-2029)

9 Asia (excluding China)

• 9.1 Asia Short-acting EPO Drugs Market Size by Type
  • 9.1.1 Asia Short-acting EPO Drugs Sales by Type (2018-2029)
  • 9.1.2 Asia Short-acting EPO Drugs Revenue by Type (2018-2029)
• 9.2 Asia Short-acting EPO Drugs Market Size by Application
  • 9.2.1 Asia Short-acting EPO Drugs Sales by Application (2018-2029)
  • 9.2.2 Asia Short-acting EPO Drugs Revenue by Application (2018-2029)
• 9.3 Asia Short-acting EPO Drugs Sales by Region
  • 9.3.1 Asia Short-acting EPO Drugs Revenue by Region: 2018 VS 2022 VS 2029
  • 9.3.2 Asia Short-acting EPO Drugs Revenue by Region (2018-2029)
  • 9.3.3 Asia Short-acting EPO Drugs Sales by Region (2018-2029)
  • 9.3.4 Japan
  • 9.3.5 South Korea
  • 9.3.6 China Taiwan
  • 9.3.7 Southeast Asia
  • 9.3.8 India

10 Middle East, Africa and Latin America

• 10.1 Middle East, Africa and Latin America Short-acting EPO Drugs Market Size by Type
  • 10.1.1 Middle East, Africa and Latin America Short-acting EPO Drugs Sales by Type (2018-2029)
  • 10.1.2 Middle East, Africa and Latin America Short-acting EPO Drugs Revenue by Type (2018-2029)
• 10.2 Middle East, Africa and Latin America Short-acting EPO Drugs Market Size by Application
  • 10.2.1 Middle East, Africa and Latin America Short-acting EPO Drugs Sales by Application (2018-2029)
  • 10.2.2 Middle East, Africa and Latin America Short-acting EPO Drugs Revenue by Application (2018-2029)
• 10.3 Middle East, Africa and Latin America Short-acting EPO Drugs Sales by Country
  • 10.3.1 Middle East, Africa and Latin America Short-acting EPO Drugs Revenue by Country: 2018 VS 2022 VS 2029
  • 10.3.2 Middle East, Africa and Latin America Short-acting EPO Drugs Revenue by Country (2018-2029)
  • 10.3.3 Middle East, Africa and Latin America Short-acting EPO Drugs Sales by Country (2018-2029)
  • 10.3.4 Brazil
  • 10.3.5 Mexico
  • 10.3.6 Turkey
  • 10.3.7 Israel
  • 10.3.8 GCC Countries

11 Company Profiles

• 11.1 Amgen
  • 11.1.1 Amgen Company Information
  • 11.1.2 Amgen Overview
  • 11.1.3 Amgen Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.1.4 Amgen Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.1.5 Amgen Recent Developments
• 11.2 Johnson & Johnson
  • 11.2.1 Johnson & Johnson Company Information
  • 11.2.2 Johnson & Johnson Overview
  • 11.2.3 Johnson & Johnson Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.2.4 Johnson & Johnson Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.2.5 Johnson & Johnson Recent Developments
• 11.3 Roche
  • 11.3.1 Roche Company Information
  • 11.3.2 Roche Overview
  • 11.3.3 Roche Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.3.4 Roche Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.3.5 Roche Recent Developments
• 11.4 Kyowa Kirin
  • 11.4.1 Kyowa Kirin Company Information
  • 11.4.2 Kyowa Kirin Overview
  • 11.4.3 Kyowa Kirin Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.4.4 Kyowa Kirin Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.4.5 Kyowa Kirin Recent Developments
• 11.5 LG Chem
  • 11.5.1 LG Chem Company Information
  • 11.5.2 LG Chem Overview
  • 11.5.3 LG Chem Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.5.4 LG Chem Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.5.5 LG Chem Recent Developments
• 11.6 Daewoong Pharmaceutical
  • 11.6.1 Daewoong Pharmaceutical Company Information
  • 11.6.2 Daewoong Pharmaceutical Overview
  • 11.6.3 Daewoong Pharmaceutical Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.6.4 Daewoong Pharmaceutical Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.6.5 Daewoong Pharmaceutical Recent Developments
• 11.7 Wockhardt
  • 11.7.1 Wockhardt Company Information
  • 11.7.2 Wockhardt Overview
  • 11.7.3 Wockhardt Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.7.4 Wockhardt Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.7.5 Wockhardt Recent Developments
• 11.8 CJ Healthcare
  • 11.8.1 CJ Healthcare Company Information
  • 11.8.2 CJ Healthcare Overview
  • 11.8.3 CJ Healthcare Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.8.4 CJ Healthcare Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.8.5 CJ Healthcare Recent Developments
• 11.9 3SBio
  • 11.9.1 3SBio Company Information
  • 11.9.2 3SBio Overview
  • 11.9.3 3SBio Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.9.4 3SBio Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.9.5 3SBio Recent Developments
• 11.10 Kexing Biopharm
  • 11.10.1 Kexing Biopharm Company Information
  • 11.10.2 Kexing Biopharm Overview
  • 11.10.3 Kexing Biopharm Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.10.4 Kexing Biopharm Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.10.5 Kexing Biopharm Recent Developments
• 11.11 Harbin Pharmaceutical Group
  • 11.11.1 Harbin Pharmaceutical Group Company Information
  • 11.11.2 Harbin Pharmaceutical Group Overview
  • 11.11.3 Harbin Pharmaceutical Group Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.11.4 Harbin Pharmaceutical Group Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.11.5 Harbin Pharmaceutical Group Recent Developments
• 11.12 Beijing Four Rings Bio-Pharmaceutical
  • 11.12.1 Beijing Four Rings Bio-Pharmaceutical Company Information
  • 11.12.2 Beijing Four Rings Bio-Pharmaceutical Overview
  • 11.12.3 Beijing Four Rings Bio-Pharmaceutical Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.12.4 Beijing Four Rings Bio-Pharmaceutical Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.12.5 Beijing Four Rings Bio-Pharmaceutical Recent Developments

12 Industry Chain and Sales Channels Analysis

• 12.1 Short-acting EPO Drugs Industry Chain Analysis
• 12.2 Short-acting EPO Drugs Key Raw Materials
  • 12.2.1 Key Raw Materials
  • 12.2.2 Raw Materials Key Suppliers
• 12.3 Short-acting EPO Drugs Production Mode & Process
• 12.4 Short-acting EPO Drugs Sales and Marketing
  • 12.4.1 Short-acting EPO Drugs Sales Channels
  • 12.4.2 Short-acting EPO Drugs Distributors
• 12.5 Short-acting EPO Drugs Customers

13 Market Dynamics

• 13.1 Short-acting EPO Drugs Industry Trends
• 13.2 Short-acting EPO Drugs Market Drivers
• 13.3 Short-acting EPO Drugs Market Challenges
• 13.4 Short-acting EPO Drugs Market Restraints

14 Key Findings in The Global Short-acting EPO Drugs Study

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Author Details
• 15.3 Disclaimer

List of Tables

• Table 1. Global Short-acting EPO Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
• Table 2. Major Manufacturers of Epoetin-alfa
• Table 3. Major Manufacturers of Epoetin-beta
• Table 4. Major Manufacturers of Darbepoetin-alfa
• Table 5. Major Manufacturers of Others
• Table 6. Global Short-acting EPO Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
• Table 7. Global Short-acting EPO Drugs Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
• Table 8. Global Short-acting EPO Drugs Revenue by Region (2018-2023) & (US$ Million)
• Table 9. Global Short-acting EPO Drugs Revenue by Region (2024-2029) & (US$ Million)
• Table 10. Global Short-acting EPO Drugs Revenue Market Share by Region (2018-2023)
• Table 11. Global Short-acting EPO Drugs Revenue Market Share by Region (2024-2029)
• Table 12. Global Short-acting EPO Drugs Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
• Table 13. Global Short-acting EPO Drugs Sales by Region (2018-2023) & (K Units)
• Table 14. Global Short-acting EPO Drugs Sales by Region (2024-2029) & (K Units)
• Table 15. Global Short-acting EPO Drugs Sales Market Share by Region (2018-2023)
• Table 16. Global Short-acting EPO Drugs Sales Market Share by Region (2024-2029)
• Table 17. Global Short-acting EPO Drugs Sales by Manufacturers (2018-2023) & (K Units)
• Table 18. Global Short-acting EPO Drugs Sales Share by Manufacturers (2018-2023)
• Table 19. Global Short-acting EPO Drugs Revenue by Manufacturers (2018-2023) & (US$ Million)
• Table 20. Global Short-acting EPO Drugs Revenue Share by Manufacturers (2018-2023)
• Table 21. Global Key Players of Short-acting EPO Drugs, Industry Ranking, 2021 VS 2022 VS 2023
• Table 22. Short-acting EPO Drugs Price by Manufacturers 2018-2023 (US$/Unit)
• Table 23. Global Short-acting EPO Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
• Table 24. Global Short-acting EPO Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Short-acting EPO Drugs as of 2022)
• Table 25. Global Key Manufacturers of Short-acting EPO Drugs, Manufacturing Base Distribution and Headquarters
• Table 26. Global Key Manufacturers of Short-acting EPO Drugs, Product Offered and Application
• Table 27. Global Key Manufacturers of Short-acting EPO Drugs, Date of Enter into This Industry
• Table 28. Mergers & Acquisitions, Expansion Plans
• Table 29. Global Short-acting EPO Drugs Sales by Type (2018-2023) & (K Units)
• Table 30. Global Short-acting EPO Drugs Sales by Type (2024-2029) & (K Units)
• Table 31. Global Short-acting EPO Drugs Sales Share by Type (2018-2023)
• Table 32. Global Short-acting EPO Drugs Sales Share by Type (2024-2029)
• Table 33. Global Short-acting EPO Drugs Revenue by Type (2018-2023) & (US$ Million)
• Table 34. Global Short-acting EPO Drugs Revenue by Type (2024-2029) & (US$ Million)
• Table 35. Global Short-acting EPO Drugs Revenue Share by Type (2018-2023)
• Table 36. Global Short-acting EPO Drugs Revenue Share by Type (2024-2029)
• Table 37. Short-acting EPO Drugs Price by Type (2018-2023) & (US$/Unit)
• Table 38. Global Short-acting EPO Drugs Price Forecast by Type (2024-2029) & (US$/Unit)
• Table 39. Global Short-acting EPO Drugs Sales by Application (2018-2023) & (K Units)
• Table 40. Global Short-acting EPO Drugs Sales by Application (2024-2029) & (K Units)
• Table 41. Global Short-acting EPO Drugs Sales Share by Application (2018-2023)
• Table 42. Global Short-acting EPO Drugs Sales Share by Application (2024-2029)
• Table 43. Global Short-acting EPO Drugs Revenue by Application (2018-2023) & (US$ Million)
• Table 44. Global Short-acting EPO Drugs Revenue by Application (2024-2029) & (US$ Million)
• Table 45. Global Short-acting EPO Drugs Revenue Share by Application (2018-2023)
• Table 46. Global Short-acting EPO Drugs Revenue Share by Application (2024-2029)
• Table 47. Short-acting EPO Drugs Price by Application (2018-2023) & (US$/Unit)
• Table 48. Global Short-acting EPO Drugs Price Forecast by Application (2024-2029) & (US$/Unit)
• Table 49. US & Canada Short-acting EPO Drugs Sales by Type (2018-2023) & (K Units)
• Table 50. US & Canada Short-acting EPO Drugs Sales by Type (2024-2029) & (K Units)
• Table 51. US & Canada Short-acting EPO Drugs Revenue by Type (2018-2023) & (US$ Million)
• Table 52. US & Canada Short-acting EPO Drugs Revenue by Type (2024-2029) & (US$ Million)
• Table 53. US & Canada Short-acting EPO Drugs Sales by Application (2018-2023) & (K Units)
• Table 54. US & Canada Short-acting EPO Drugs Sales by Application (2024-2029) & (K Units)
• Table 55. US & Canada Short-acting EPO Drugs Revenue by Application (2018-2023) & (US$ Million)
• Table 56. US & Canada Short-acting EPO Drugs Revenue by Application (2024-2029) & (US$ Million)
• Table 57. US & Canada Short-acting EPO Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
• Table 58. US & Canada Short-acting EPO Drugs Revenue by Country (2018-2023) & (US$ Million)
• Table 59. US & Canada Short-acting EPO Drugs Revenue by Country (2024-2029) & (US$ Million)
• Table 60. US & Canada Short-acting EPO Drugs Sales by Country (2018-2023) & (K Units)
• Table 61. US & Canada Short-acting EPO Drugs Sales by Country (2024-2029) & (K Units)
• Table 62. Europe Short-acting EPO Drugs Sales by Type (2018-2023) & (K Units)
• Table 63. Europe Short-acting EPO Drugs Sales by Type (2024-2029) & (K Units)
• Table 64. Europe Short-acting EPO Drugs Revenue by Type (2018-2023) & (US$ Million)
• Table 65. Europe Short-acting EPO Drugs Revenue by Type (2024-2029) & (US$ Million)
• Table 66. Europe Short-acting EPO Drugs Sales by Application (2018-2023) & (K Units)
• Table 67. Europe Short-acting EPO Drugs Sales by Application (2024-2029) & (K Units)
• Table 68. Europe Short-acting EPO Drugs Revenue by Application (2018-2023) & (US$ Million)
• Table 69. Europe Short-acting EPO Drugs Revenue by Application (2024-2029) & (US$ Million)
• Table 70. Europe Short-acting EPO Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
• Table 71. Europe Short-acting EPO Drugs Revenue by Country (2018-2023) & (US$ Million)
• Table 72. Europe Short-acting EPO Drugs Revenue by Country (2024-2029) & (US$ Million)
• Table 73. Europe Short-acting EPO Drugs Sales by Country (2018-2023) & (K Units)
• Table 74. Europe Short-acting EPO Drugs Sales by Country (2024-2029) & (K Units)
• Table 75. China Short-acting EPO Drugs Sales by Type (2018-2023) & (K Units)
• Table 76. China Short-acting EPO Drugs Sales by Type (2024-2029) & (K Units)
• Table 77. China Short-acting EPO Drugs Revenue by Type (2018-2023) & (US$ Million)
• Table 78. China Short-acting EPO Drugs Revenue by Type (2024-2029) & (US$ Million)
• Table 79. China Short-acting EPO Drugs Sales by Application (2018-2023) & (K Units)
• Table 80. China Short-acting EPO Drugs Sales by Application (2024-2029) & (K Units)
• Table 81. China Short-acting EPO Drugs Revenue by Application (2018-2023) & (US$ Million)
• Table 82. China Short-acting EPO Drugs Revenue by Application (2024-2029) & (US$ Million)
• Table 83. Asia Short-acting EPO Drugs Sales by Type (2018-2023) & (K Units)
• Table 84. Asia Short-acting EPO Drugs Sales by Type (2024-2029) & (K Units)
• Table 85. Asia Short-acting EPO Drugs Revenue by Type (2018-2023) & (US$ Million)
• Table 86. Asia Short-acting EPO Drugs Revenue by Type (2024-2029) & (US$ Million)
• Table 87. Asia Short-acting EPO Drugs Sales by Application (2018-2023) & (K Units)
• Table 88. Asia Short-acting EPO Drugs Sales by Application (2024-2029) & (K Units)
• Table 89. Asia Short-acting EPO Drugs Revenue by Application (2018-2023) & (US$ Million)
• Table 90. Asia Short-acting EPO Drugs Revenue by Application (2024-2029) & (US$ Million)
• Table 91. Asia Short-acting EPO Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
• Table 92. Asia Short-acting EPO Drugs Revenue by Region (2018-2023) & (US$ Million)
• Table 93. Asia Short-acting EPO Drugs Revenue by Region (2024-2029) & (US$ Million)
• Table 94. Asia Short-acting EPO Drugs Sales by Region (2018-2023) & (K Units)
• Table 95. Asia Short-acting EPO Drugs Sales by Region (2024-2029) & (K Units)
• Table 96. Middle East, Africa and Latin America Short-acting EPO Drugs Sales by Type (2018-2023) & (K Units)
• Table 97. Middle East, Africa and Latin America Short-acting EPO Drugs Sales by Type (2024-2029) & (K Units)
• Table 98. Middle East, Africa and Latin America Short-acting EPO Drugs Revenue by Type (2018-2023) & (US$ Million)
• Table 99. Middle East, Africa and Latin America Short-acting EPO Drugs Revenue by Type (2024-2029) & (US$ Million)
• Table 100. Middle East, Africa and Latin America Short-acting EPO Drugs Sales by Application (2018-2023) & (K Units)
• Table 101. Middle East, Africa and Latin America Short-acting EPO Drugs Sales by Application (2024-2029) & (K Units)
• Table 102. Middle East, Africa and Latin America Short-acting EPO Drugs Revenue by Application (2018-2023) & (US$ Million)
• Table 103. Middle East, Africa and Latin America Short-acting EPO Drugs Revenue by Application (2024-2029) & (US$ Million)
• Table 104. Middle East, Africa and Latin America Short-acting EPO Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
• Table 105. Middle East, Africa and Latin America Short-acting EPO Drugs Revenue by Country (2018-2023) & (US$ Million)
• Table 106. Middle East, Africa and Latin America Short-acting EPO Drugs Revenue by Country (2024-2029) & (US$ Million)
• Table 107. Middle East, Africa and Latin America Short-acting EPO Drugs Sales by Country (2018-2023) & (K Units)
• Table 108. Middle East, Africa and Latin America Short-acting EPO Drugs Sales by Country (2024-2029) & (K Units)
• Table 109. Amgen Company Information
• Table 110. Amgen Description and Major Businesses
• Table 111. Amgen Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 112. Amgen Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 113. Amgen Recent Developments
• Table 114. Johnson & Johnson Company Information
• Table 115. Johnson & Johnson Description and Major Businesses
• Table 116. Johnson & Johnson Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 117. Johnson & Johnson Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 118. Johnson & Johnson Recent Developments
• Table 119. Roche Company Information
• Table 120. Roche Description and Major Businesses
• Table 121. Roche Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 122. Roche Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 123. Roche Recent Developments
• Table 124. Kyowa Kirin Company Information
• Table 125. Kyowa Kirin Description and Major Businesses
• Table 126. Kyowa Kirin Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 127. Kyowa Kirin Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 128. Kyowa Kirin Recent Developments
• Table 129. LG Chem Company Information
• Table 130. LG Chem Description and Major Businesses
• Table 131. LG Chem Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 132. LG Chem Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 133. LG Chem Recent Developments
• Table 134. Daewoong Pharmaceutical Company Information
• Table 135. Daewoong Pharmaceutical Description and Major Businesses
• Table 136. Daewoong Pharmaceutical Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 137. Daewoong Pharmaceutical Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 138. Daewoong Pharmaceutical Recent Developments
• Table 139. Wockhardt Company Information
• Table 140. Wockhardt Description and Major Businesses
• Table 141. Wockhardt Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 142. Wockhardt Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 143. Wockhardt Recent Developments
• Table 144. CJ Healthcare Company Information
• Table 145. CJ Healthcare Description and Major Businesses
• Table 146. CJ Healthcare Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 147. CJ Healthcare Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 148. CJ Healthcare Recent Developments
• Table 149. 3SBio Company Information
• Table 150. 3SBio Description and Major Businesses
• Table 151. 3SBio Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 152. 3SBio Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 153. 3SBio Recent Developments
• Table 154. Kexing Biopharm Company Information
• Table 155. Kexing Biopharm Description and Major Businesses
• Table 156. Kexing Biopharm Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 157. Kexing Biopharm Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 158. Kexing Biopharm Recent Developments
• Table 159. Harbin Pharmaceutical Group Company Information
• Table 160. Harbin Pharmaceutical Group Description and Major Businesses
• Table 161. Harbin Pharmaceutical Group Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 162. Harbin Pharmaceutical Group Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 163. Harbin Pharmaceutical Group Recent Developments
• Table 164. Beijing Four Rings Bio-Pharmaceutical Company Information
• Table 165. Beijing Four Rings Bio-Pharmaceutical Description and Major Businesses
• Table 166. Beijing Four Rings Bio-Pharmaceutical Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
• Table 167. Beijing Four Rings Bio-Pharmaceutical Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 168. Beijing Four Rings Bio-Pharmaceutical Recent Developments
• Table 169. Key Raw Materials Lists
• Table 170. Raw Materials Key Suppliers Lists
• Table 171. Short-acting EPO Drugs Distributors List
• Table 172. Short-acting EPO Drugs Customers List
• Table 173. Short-acting EPO Drugs Market Trends
• Table 174. Short-acting EPO Drugs Market Drivers
• Table 175. Short-acting EPO Drugs Market Challenges
• Table 176. Short-acting EPO Drugs Market Restraints
• Table 177. Research Programs/Design for This Report
• Table 178. Key Data Information from Secondary Sources
• Table 179. Key Data Information from Primary Sources

List of Figures

• Figure 1. Short-acting EPO Drugs Product Picture
• Figure 2. Global Short-acting EPO Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
• Figure 3. Global Short-acting EPO Drugs Market Share by Type in 2022 & 2029
• Figure 4. Epoetin-alfa Product Picture
• Figure 5. Epoetin-beta Product Picture
• Figure 6. Darbepoetin-alfa Product Picture
• Figure 7. Others Product Picture
• Figure 8. Global Short-acting EPO Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
• Figure 9. Global Short-acting EPO Drugs Market Share by Application in 2022 & 2029
• Figure 10. Anemia
• Figure 11. Kidney Disorders
• Figure 12. Others
• Figure 13. Short-acting EPO Drugs Report Years Considered
• Figure 14. Global Short-acting EPO Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
• Figure 15. Global Short-acting EPO Drugs Revenue 2018-2029 (US$ Million)
• Figure 16. Global Short-acting EPO Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2029
• Figure 17. Global Short-acting EPO Drugs Revenue Market Share by Region (2018-2029)
• Figure 18. Global Short-acting EPO Drugs Sales 2018-2029 ((K Units)
• Figure 19. Global Short-acting EPO Drugs Sales Market Share by Region (2018-2029)
• Figure 20. US & Canada Short-acting EPO Drugs Sales YoY (2018-2029) & (K Units)
• Figure 21. US & Canada Short-acting EPO Drugs Revenue YoY (2018-2029) & (US$ Million)
• Figure 22. Europe Short-acting EPO Drugs Sales YoY (2018-2029) & (K Units)
• Figure 23. Europe Short-acting EPO Drugs Revenue YoY (2018-2029) & (US$ Million)
• Figure 24. China Short-acting EPO Drugs Sales YoY (2018-2029) & (K Units)
• Figure 25. China Short-acting EPO Drugs Revenue YoY (2018-2029) & (US$ Million)
• Figure 26. Asia (excluding China) Short-acting EPO Drugs Sales YoY (2018-2029) & (K Units)
• Figure 27. Asia (excluding China) Short-acting EPO Drugs Revenue YoY (2018-2029) & (US$ Million)
• Figure 28. Middle East, Africa and Latin America Short-acting EPO Drugs Sales YoY (2018-2029) & (K Units)
• Figure 29. Middle East, Africa and Latin America Short-acting EPO Drugs Revenue YoY (2018-2029) & (US$ Million)
• Figure 30. The Short-acting EPO Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
• Figure 31. The Top 5 and 10 Largest Manufacturers of Short-acting EPO Drugs in the World: Market Share by Short-acting EPO Drugs Revenue in 2022
• Figure 32. Global Short-acting EPO Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
• Figure 33. Global Short-acting EPO Drugs Sales Market Share by Type (2018-2029)
• Figure 34. Global Short-acting EPO Drugs Revenue Market Share by Type (2018-2029)
• Figure 35. Global Short-acting EPO Drugs Sales Market Share by Application (2018-2029)
• Figure 36. Global Short-acting EPO Drugs Revenue Market Share by Application (2018-2029)
• Figure 37. US & Canada Short-acting EPO Drugs Sales Market Share by Type (2018-2029)
• Figure 38. US & Canada Short-acting EPO Drugs Revenue Market Share by Type (2018-2029)
• Figure 39. US & Canada Short-acting EPO Drugs Sales Market Share by Application (2018-2029)
• Figure 40. US & Canada Short-acting EPO Drugs Revenue Market Share by Application (2018-2029)
• Figure 41. US & Canada Short-acting EPO Drugs Revenue Share by Country (2018-2029)
• Figure 42. US & Canada Short-acting EPO Drugs Sales Share by Country (2018-2029)
• Figure 43. U.S. Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
• Figure 44. Canada Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
• Figure 45. Europe Short-acting EPO Drugs Sales Market Share by Type (2018-2029)
• Figure 46. Europe Short-acting EPO Drugs Revenue Market Share by Type (2018-2029)
• Figure 47. Europe Short-acting EPO Drugs Sales Market Share by Application (2018-2029)
• Figure 48. Europe Short-acting EPO Drugs Revenue Market Share by Application (2018-2029)
• Figure 49. Europe Short-acting EPO Drugs Revenue Share by Country (2018-2029)
• Figure 50. Europe Short-acting EPO Drugs Sales Share by Country (2018-2029)
• Figure 51. Germany Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
• Figure 52. France Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
• Figure 53. U.K. Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
• Figure 54. Italy Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
• Figure 55. Russia Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
• Figure 56. China Short-acting EPO Drugs Sales Market Share by Type (2018-2029)
• Figure 57. China Short-acting EPO Drugs Revenue Market Share by Type (2018-2029)
• Figure 58. China Short-acting EPO Drugs Sales Market Share by Application (2018-2029)
• Figure 59. China Short-acting EPO Drugs Revenue Market Share by Application (2018-2029)
• Figure 60. Asia Short-acting EPO Drugs Sales Market Share by Type (2018-2029)
• Figure 61. Asia Short-acting EPO Drugs Revenue Market Share by Type (2018-2029)
• Figure 62. Asia Short-acting EPO Drugs Sales Market Share by Application (2018-2029)
• Figure 63. Asia Short-acting EPO Drugs Revenue Market Share by Application (2018-2029)
• Figure 64. Asia Short-acting EPO Drugs Revenue Share by Region (2018-2029)
• Figure 65. Asia Short-acting EPO Drugs Sales Share by Region (2018-2029)
• Figure 66. Japan Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
• Figure 67. South Korea Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
• Figure 68. China Taiwan Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
• Figure 69. Southeast Asia Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
• Figure 70. India Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
• Figure 71. Middle East, Africa and Latin America Short-acting EPO Drugs Sales Market Share by Type (2018-2029)
• Figure 72. Middle East, Africa and Latin America Short-acting EPO Drugs Revenue Market Share by Type (2018-2029)
• Figure 73. Middle East, Africa and Latin America Short-acting EPO Drugs Sales Market Share by Application (2018-2029)
• Figure 74. Middle East, Africa and Latin America Short-acting EPO Drugs Revenue Market Share by Application (2018-2029)
• Figure 75. Middle East, Africa and Latin America Short-acting EPO Drugs Revenue Share by Country (2018-2029)
• Figure 76. Middle East, Africa and Latin America Short-acting EPO Drugs Sales Share by Country (2018-2029)
• Figure 77. Brazil Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
• Figure 78. Mexico Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
• Figure 79. Turkey Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
• Figure 80. Israel Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
• Figure 81. GCC Countries Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
• Figure 82. Short-acting EPO Drugs Value Chain
• Figure 83. Short-acting EPO Drugs Production Process
• Figure 84. Channels of Distribution
• Figure 85. Distributors Profiles
• Figure 86. Bottom-up and Top-down Approaches for This Report
• Figure 87. Data Triangulation
• Figure 88. Key Executives Interviewed